Caltech Logo

Frontiers in Chemical Biology Seminar

Tuesday, November 26, 2019
4:00pm to 5:00pm
Add to Cal
Noyes 153 (J. Holmes Sturdivant Lecture Hall)
Reimagining Druggability using Chemoproteomic Platforms
Dan Nomura, Professor, Department of Chemistry, Molecular and Cell Biology, and Nutritional Sciences and Toxicology, UC-Berkeley,

The Nomura Research Group is focused on redefining druggability using chemoproteomic platforms to develop transformative medicines. One of the greatest challenges that we face in discovering new disease therapies is that most proteins are considered “undruggable,” in that most proteins do not possess known binding pockets or “druggable hotspots” that small-molecules can bind to modulate protein function. Our research group addresses this challenge by advancing and applying chemoproteomic platforms to discover and pharmacologically target unique and novel druggable hotspots for disease therapy. We currently have three major research directions. Our first major focus is on developing and applying chemoproteomics-enabled covalent ligand discovery approaches to rapidly discover small-molecule therapeutic leads that target unique and novel druggable hotspots for undruggable protein targets and pathways. Our second research area focuses on discovering and exploiting unique druggable modalities accessed by natural products. Our third research area focuses on using chemoproteomics-enabled covalent ligand discovery platforms to expand the scope of targeted protein degradation and to discover new induced proximity-based therapeutic modalities. Collectively, our lab is focused on developing next-generation transformative medicines through pioneering innovative chemical technologies to overcome challenges in drug discovery.

For more information, please contact Annette Luymes by phone at x6016 or by email at aluymes@caltech.edu.